US Pharma MarketingThe post SystImmune doses first patient in Phase III trial for ES-SCLC appeared first on Clinical Trials Arena.
SystImmune doses first patient in Phase III trial for ES-SCLC
SystImmune has dosed the first patient in its global Phase III clinical trial, BrenDeLL-Lung01, assessing BL-M14D1 combined with atezolizumab in those with previously untreated ES-SCLC. The post SystImmune doses first patient in Phase III trial for ES-SCLC appeared first on Clinical Trials Arena .
SystImmune has dosed the first patient in its global Phase III clinical trial, BrenDeLL-Lung01, assessing BL-M14D1 combined with atezolizumab in those with previously untreated ES-SCLC.
Source: Clinical Trials Arena